2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理

2021-01-12 Fleischner学会 Radiology.2021 Jan 12

2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺

中文标题：

英文标题：

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

发布机构：

Fleischner学会

发布日期：

2021-01-12

简要介绍：

2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺炎的简化诊断标准，CT检查以及管理建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=249a71c002039072, title=2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理, enTitle=Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society, guiderFrom=Radiology.2021 Jan 12, authorId=0, author=, summary=2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺, cover=https://img.medsci.cn/2021121/1611241283233_2020535.jpg, journalId=0, articlesId=null, associationId=902, associationName=Fleischner学会, associationIntro=Fleischner学会是一个国际的多学科胸部放射医学会，致力于通过胸部放射学诊断治疗胸部疾病。, copyright=0, guiderPublishedTime=Tue Jan 12 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺炎的简化诊断标准，CT检查以及管理建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=36163, tagName=免疫检查点抑制剂), TagDto(tagId=109459, tagName=药物相关性肺炎)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=36163, guiderKeyword=免疫检查点抑制剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2653, appHits=160, showAppHits=0, pcHits=548, showPcHits=2493, likes=0, shares=21, comments=7, approvalStatus=1, publishedTime=Thu Jan 21 23:41:11 CST 2021, publishedTimeString=2021-01-12, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Jan 21 23:02:30 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 13:50:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑.pdf)])

2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
2021-12-18 luosujuan1984

棒

121 0
[GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
2021-09-14 ms8000000063630784

好

103 0
[GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
2021-09-14 ms8000000063630784

学习了

105 0
[GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
2021-06-04 ms1000001134092964

学习

106 0
[GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
2021-03-31 121f8ba0m90暂无昵称

学习了

115 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理

相关指南

拓展阅读

科室

工具

服务